Fusion protein of single domain antibody and procoagulant
US12391754B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2021 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | May 20, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and especially on a subset of activated platelets, coated platelets. Furthermore, the present invention relates to fusion proteins comprising sdAbs against TLT-1 and an extracellular (soluble) domain of tissue factor (sTF), to direct targeting of such fusion proteins to activated platelets at the site of injury through binding of the sdAbs to TLT-1, a membrane protein receptor that is only present on activated platelets. Specific interaction of sdAbs with the TLT-1 receptor positions the sTF domain of the fusion to interact with, and activate, FVII. As a result, a targeted procoagulant effect is achieved at the site of injury via activated platelets. The fusion proteins are useful to treat individuals that have a bleeding disorder, such as hemophilia A, hemophilia B, or acute bleeding due to traumatic injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.